ASTANA, July 14 — The global vaccine market, a sector that directly shapes public health outcomes from Central Asia to the Americas, rests on a foundation of scientific achievement that has been centuries in the making. The World Health Organization estimates vaccines prevent 2-3 million deaths per year globally, a figure that underscores the economic and social stake nations have in maintaining robust immunization programs. The mechanism of action is precise.
Vaccines stimulate the adaptive immune system to develop immunological memory without causing the disease. They typically contain weakened or inactivated forms of a pathogen, or pieces of the pathogen known as antigens, such as proteins or genetic material like mRNA.
This process is what allows populations to build herd immunity without bearing the full cost of an outbreak.
From Jenner to mRNA: A Timeline of Trade and Health
The first vaccine was developed by Edward Jenner in 1796 against smallpox. The World Health Organization declared smallpox eradicated in 1980, a milestone that remains the gold standard for vaccine-driven disease control. Louis Pasteur later developed vaccines for rabies in 1885 and anthrax in 1881, establishing principles that would underpin the modern biologics industry.
The 20th century saw a rapid expansion of the vaccine toolkit. Vaccines were developed for diphtheria in the 1920s, tetanus in the 1920s, pertussis in the 1940s, and polio—with an inactivated version by Jonas Salk in 1955 and an oral version by Albert Sabin in 1961.
Measles vaccine arrived in 1963, mumps in 1967, rubella in 1969, and hepatitis B in 1981.
The COVID-19 Pivot and Central Asian Implications
The COVID-19 pandemic spurred the rapid development of mRNA vaccines by Pfizer-BioNTech and Moderna. These received emergency use authorization in December 2020. The technology uses messenger RNA to instruct cells to produce the spike protein of SARS-CoV-2, triggering an immune response.
For resource-constrained regions, including parts of Central Asia, the speed of this development demonstrated how quickly vaccine supply chains can be reoriented when global demand concentrates. Vaccination has led to the eradication of smallpox and the near-elimination of polio.
As of 2023, only two countries—Afghanistan and Pakistan—still reported endemic wild poliovirus. This narrowing of the disease map represents a significant reduction in the logistical and financial burden of maintaining global polio surveillance. The economic stake for Kazakhstan and its neighbors remains clear: a population protected by vaccines is a workforce that stays productive, and a healthcare system that avoids the crushing costs of treating preventable diseases.
The development of next-generation vaccines, from mRNA platforms to novel adjuvants, will continue to be a focus for both public health agencies and private manufacturers looking to secure supply contracts. Consult your doctor for medical advice.
